<![CDATA[Shire Plc - Shire News Feed]]>

<![CDATA[Shire Plc - Shire News Feed]]> Wed, 01 Feb 2012 11:42:30 +0000 <![CDATA[Total Voting Rights]]> 01 Feb 2012 11:42:30 GMT <![CDATA[Shire and Sangamo Collaborate to Develop Therapeutics for the Treatment of Hemophilia and Other Monogenic Diseases]]> 01 Feb 2012 11:39:57 GMT <![CDATA[Full Year 2011 results date notification – February 9, 2012]]> 31 Jan 2012 10:58:54 GMT <![CDATA[Notification of major interests in shares]]> 23 Jan 2012 11:44:20 GMT <![CDATA[Shire Acquires US Rights to Resolor® (prucalopride)]]> 10 Jan 2012 10:02:37 GMT <![CDATA[Shire’s VENVANSE® (lisdexamfetamine dimesylate) Marketing Application accepted for review in Europe]]> 05 Jan 2012 11:57:43 GMT <![CDATA[Total Voting Rights]]> 03 Jan 2012 11:51:57 GMT <![CDATA[Share dealing by a Person Discharging Managerial Responsibility]]> 30 Dec 2011 09:47:22 GMT <![CDATA[Shire plc Board and Committee Changes]]> 15 Dec 2011 02:17:16 GMT <![CDATA[Director/PDMR Shareholding]]> 14 Dec 2011 10:01:56 GMT <![CDATA[Director/PDMR Shareholding]]> 12 Dec 2011 04:14:45 GMT <![CDATA[Shire Reports Positive Phase II Results for Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules, (CII)]]> 08 Dec 2011 03:59:14 GMT <![CDATA[ProAmatine® Update: Path Forward Agreed]]> 02 Dec 2011 06:18:14 GMT <![CDATA[ADDERALL® (mixed salts of a single-entity amphetamine product) Supply Clarification]]> 01 Dec 2011 04:38:15 GMT <![CDATA[Director/PDMR Shareholding]]> 01 Dec 2011 12:07:05 GMT <![CDATA[Total Voting Rights]]> 01 Dec 2011 12:02:04 GMT <![CDATA[Block listing six monthly return]]> 24 Nov 2011 12:04:28 GMT <![CDATA[Shire Announces Regulatory Filings in US and EU for New Manufacturing Facility ]]> 22 Nov 2011 08:35:23 GMT <![CDATA[Director/PDMR Shareholding]]> 21 Nov 2011 04:18:51 GMT <![CDATA[BRAVE Awards Recipients Announced]]> 18 Nov 2011 05:26:17 GMT <![CDATA[Shire Announces Strategic Partnership for ADHD Medicines in Japan with Shionogi & Co., Ltd. ]]> 18 Nov 2011 07:35:09 GMT <![CDATA[Director/PDMR Shareholding]]> 07 Nov 2011 11:51:11 GMT <![CDATA[PDMR Share Transactions]]> 02 Nov 2011 03:00:00 GMT <![CDATA[Total Voting Rights]]> 01 Nov 2011 11:25:10 GMT <![CDATA[Director Declaration]]> 01 Nov 2011 10:07:21 GMT <![CDATA[Continued strong product sales performance in Q3: On track to deliver significant 2011 earnings growth]]> 28 Oct 2011 11:00:20 GMT <![CDATA[EU study shows once-daily lisdexamfetamine dimesylate (LDX) effective for symptom control in children and adolescents with ADHD]]> 21 Oct 2011 12:02:07 GMT <![CDATA[Bloomberg interview - Shire To Expand in Regenerative Medicine, CEO Says]]> 20 Oct 2011 10:19:12 GMT <![CDATA[Shire Canada grants SickKids $200,000 to support paediatric research and ADHD]]> 13 Oct 2011 12:15:44 GMT <![CDATA[Third quarter 2011 results date notification – October 28, 2011]]> 13 Oct 2011 07:33:37 GMT <![CDATA[Total Voting Rights]]> 03 Oct 2011 02:56:42 GMT <![CDATA[Director/PDMR Shareholding]]> 30 Sep 2011 04:37:43 GMT <![CDATA[Director/PDMR Shareholding]]> 26 Sep 2011 04:22:19 GMT <![CDATA[Shire Provides Update on ProAmatine® (midodrine HCl)]]> 22 Sep 2011 04:57:38 GMT <![CDATA[Elections for Interim Dividend in Respect of the Six Months to June 30, 2011]]> 01 Sep 2011 03:54:33 GMT <![CDATA[Total Voting Rights]]> 01 Sep 2011 01:35:49 GMT <![CDATA[FDA Approves Shire’s FIRAZYR® (icatibant injection) for Acute Attacks of Hereditary Angioedema (HAE)]]> 25 Aug 2011 09:57:10 GMT <![CDATA[Top-Line Results from Pivotal Trial of Dermagraft® for Venous Leg Ulcers]]> 24 Aug 2011 03:10:43 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 12 Aug 2011 12:40:20 GMT <![CDATA[Half Yearly Report]]> 11 Aug 2011 03:24:04 GMT <![CDATA[Director/PDMR Shareholding]]> 03 Aug 2011 02:34:58 GMT <![CDATA[Director/PDMR Shareholding ]]> 02 Aug 2011 06:18:04 GMT <![CDATA[Director/PDMR Shareholding ]]> 01 Aug 2011 05:40:50 GMT <![CDATA[Total Voting Rights]]> 01 Aug 2011 10:26:20 GMT <![CDATA[Notification of major interests in shares]]> 29 Jul 2011 05:02:24 GMT <![CDATA[Shire's quarterly revenues grow by 25% to $1 billion for the first time]]> 28 Jul 2011 11:23:05 GMT <![CDATA[Board Changes]]> 27 Jul 2011 11:13:36 GMT <![CDATA[Lialda® (Mesalamine) Now Approved in U.S. for Maintenance of Remission of Ulcerative Colitis]]> 18 Jul 2011 10:58:25 GMT <![CDATA[Second quarter 2011 results date notification – July 28, 2011]]> 15 Jul 2011 11:57:52 GMT <![CDATA[Shire named “Business of the Year” at 2011 First Women Awards]]> 08 Jul 2011 04:34:43 GMT <![CDATA[Shire files lawsuits against Watson and Roxane for infringement of VYVANSE® (lisdexamfetamine dimesylate) patents]]> 07 Jul 2011 11:17:57 GMT <![CDATA[Shire files lawsuits against Sandoz and Amneal for infringement of VYVANSE®]]> 01 Jul 2011 04:45:34 GMT <![CDATA[Total Voting Rights]]> 01 Jul 2011 12:08:20 GMT <![CDATA[Shire completes acquisition of Advanced BioHealing, Inc.]]> 28 Jun 2011 02:28:56 GMT <![CDATA[Shire named "Company of the Year" at Mediscience Awards for second consecutive year]]> 27 Jun 2011 11:07:50 GMT <![CDATA[European Authorities Approve New Manufacturing Facility for Shire’s REPLAGAL® (agalsidase alfa)]]> 24 Jun 2011 02:23:54 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 24 Jun 2011 01:43:21 GMT <![CDATA[FDA Advisory Committee Strongly Recommends Approval and Self-Administration of FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema]]> 23 Jun 2011 10:47:35 GMT <![CDATA[Shire Launches BRAVE Awards to Recognize Caregivers]]> 21 Jun 2011 04:05:30 GMT <![CDATA[Director/PDMR Shareholding]]> 21 Jun 2011 03:25:56 GMT <![CDATA[Shire Launches First BRAVE Awards to Recognise Carers]]> 21 Jun 2011 10:05:48 GMT <![CDATA[Maroon 5 Lead Singer Adam Levine Raises Awareness of Attention-Deficit/Hyperactivity Disorder in Young Adults and Adults With "Own It"]]> 20 Jun 2011 04:27:45 GMT <![CDATA[Director/PDMR Shareholding]]> 17 Jun 2011 03:19:07 GMT <![CDATA[Shire Announces Judges Panel for New Scholarship Program for Students Diagnosed with ADHD]]> 14 Jun 2011 06:13:18 GMT <![CDATA[Health Canada grants MEZAVANT® new expanded indication for maintenance of remission of Ulcerative Colitis]]> 07 Jun 2011 10:00:31 GMT <![CDATA[Total Voting Rights]]> 01 Jun 2011 05:51:37 GMT <![CDATA[First Results of European Survey Show Significant Impact Of ADHD At School And Home, Yet Parents Wait Over Two Years for An ADHD Diagnosis]]> 28 May 2011 04:59:00 GMT <![CDATA[Calling All Students Diagnosed with ADHD – There’s a Scholarship for You!]]> 25 May 2011 06:09:01 GMT <![CDATA[Shire Receives VYVANSE® Paragraph IV Notice Letters]]> 25 May 2011 10:38:24 GMT <![CDATA[Block listing six monthly return]]> 24 May 2011 05:02:03 GMT <![CDATA[Shire Receives VYVANSE® Paragraph IV Notice Letter]]> 19 May 2011 02:51:53 GMT <![CDATA[Shire to establish new Regenerative Medicine business unit through cash acquisition of Advanced BioHealing, Inc., including US marketed DERMAGRAFT®]]> 17 May 2011 09:08:09 GMT <![CDATA[Bloomberg interview with Angus Russell, CEO]]> 12 May 2011 11:18:00 GMT <![CDATA[Director/PDMR Shareholding]]> 09 May 2011 05:35:28 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 06 May 2011 11:44:23 GMT <![CDATA[Director Declaration]]> 04 May 2011 03:10:52 GMT <![CDATA[Total Voting Rights]]> 03 May 2011 11:51:22 GMT <![CDATA[Shire delivers a strong first quarter performance]]> 28 Apr 2011 02:40:46 GMT <![CDATA[Shire Reports Positive Results from Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules (CII) as Adjunctive Treatment in Predominant Negative Symptom Schizophrenia]]> 28 Apr 2011 02:31:21 GMT <![CDATA[Results of the Annual General Meeting]]> 26 Apr 2011 06:59:29 GMT <![CDATA[First quarter 2011 results date notification – April 28, 2011]]> 21 Apr 2011 12:19:53 GMT <![CDATA[Notification of major interests in shares ]]> 19 Apr 2011 02:12:02 GMT <![CDATA[Shire files lawsuit against Watson Pharmaceuticals, Inc. for infringement of ADDERALL XR® patents and for breach of contract.]]> 06 Apr 2011 06:50:58 GMT <![CDATA[Director/PDMR Shareholding]]> 01 Apr 2011 04:04:20 GMT <![CDATA[Total Voting Rights]]> 01 Apr 2011 02:15:59 GMT <![CDATA[Annual Information Update]]> 01 Apr 2011 11:23:44 GMT <![CDATA[Notification of major interests in shares]]> 29 Mar 2011 01:46:22 GMT <![CDATA[2010 Annual Report – DTR 6.3.5 Disclosure]]> 24 Mar 2011 10:38:15 GMT <![CDATA[FDA Assigns PDUFA Date for Shire’s FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema]]> 21 Mar 2011 10:03:08 GMT <![CDATA[Shire Presents Data at ACMG for Fabry and Gaucher Patients Who Switched to Replagal® (agalsidase alfa) and VPRIV® (velaglucerase alfa for injection)]]> 21 Mar 2011 09:16:42 GMT <![CDATA[European Commission Approves Self-Administration Label for FIRAZYR® (icatibant) for the Symptomatic Treatment of Acute Hereditary Angioedema Attacks]]> 03 Mar 2011 09:38:04 GMT <![CDATA[Correction: Director/PDMR Shareholding]]> 02 Mar 2011 11:54:35 GMT <![CDATA[Director/PDMR Shareholding]]> 01 Mar 2011 05:45:20 GMT <![CDATA[Total Voting Rights]]> 01 Mar 2011 11:55:25 GMT <![CDATA[Elections for Interim Dividend in Respect of the Six Months to December 31, 2010]]> 01 Mar 2011 11:05:33 GMT <![CDATA[FDA Approves INTUNIV® (guanfacine) Extended-Release Tablets for Use as Adjunctive Therapy to Stimulants for the Treatment of ADHD in Children and Adolescents]]> 28 Feb 2011 11:06:25 GMT <![CDATA[Shire Supports World Rare Disease Day 2011 ]]> 28 Feb 2011 10:59:22 GMT <![CDATA[Shire Files Complete Response to FDA’s Not Approvable Letter for FIRAZYR® (icatibant) for the Treatment of Acute Attacks of Hereditary Angioedema]]> 28 Feb 2011 10:49:55 GMT <![CDATA[Shire Receives new Paragraph IV Notice Letter From Watson for ADDERALL XR®]]> 24 Feb 2011 03:43:17 GMT <![CDATA[Outstanding 2010 results: Non GAAP EPS up 21% to $4.23. Good earnings growth expected in 2011.]]> 10 Feb 2011 10:26:09 GMT <![CDATA[Shire Strengthens Specialty Pharmaceuticals Team with Senior R&D Appointments]]> 08 Feb 2011 03:32:07 GMT <![CDATA[Santé Canada approuve Vyvanse® pour le traitement du TDAH chez les adolescents et les adultes ]]> 02 Feb 2011 06:55:06 GMT <![CDATA[Health Canada Approves Vyvanse® for the Treatment of ADHD in Adolescents and Adults ]]> 02 Feb 2011 06:43:11 GMT <![CDATA[Total voting Rights]]> 01 Feb 2011 02:12:06 GMT <![CDATA[Full Year 2010 results date notification – February 10, 2011]]> 31 Jan 2011 04:02:16 GMT <![CDATA[Shire Appoints New Head of European Government Relations and Public Policy]]> 27 Jan 2011 11:14:51 GMT <![CDATA[Shire Recognized by ISPE Facility of the Year Awards Program]]> 24 Jan 2011 09:29:56 GMT <![CDATA[Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules CII in Excessive Daytime Sleepiness Model]]> 10 Jan 2011 01:52:39 GMT <![CDATA[Total Voting Rights]]> 04 Jan 2011 01:53:11 GMT <![CDATA[INTUNIV™ - Shire Files Suit against Impax and Watson]]> 03 Dec 2010 10:34:27 GMT <![CDATA[VPRIVMC (vélaglucérase alfa) est approuvé au Canada pour le traitement de la maladie de Gaucher de type 1 ]]> 01 Dec 2010 02:37:26 GMT <![CDATA[Total Voting Rights]]> 01 Dec 2010 01:37:46 GMT <![CDATA[Shire Reports Positive Efficacy and Safety Results From FAST-3 Study of FIRAZYR® (icatibant) for Acute Attacks of Hereditary Angioedema]]> 01 Dec 2010 12:49:56 GMT <![CDATA[VPRIV® (velaglucerase alfa) Approved in Canada for the Treatment of Type I Gaucher Disease]]> 01 Dec 2010 12:28:27 GMT <![CDATA[Block listing six monthly return]]> 23 Nov 2010 02:55:02 GMT <![CDATA[FDA Approves Vyvanse® (lisdexamfetamine dimesylate) Capsules CII for the Treatment of ADHD in Adolescents]]> 15 Nov 2010 03:55:51 GMT <![CDATA[Five-Year Market Exclusivity for VYVANSE® Upheld]]> 10 Nov 2010 10:32:53 GMT <![CDATA[Shire finalises its acquisition of Movetis NV following completion of the Squeeze-Out Process]]> 09 Nov 2010 11:21:02 GMT <![CDATA[Shire Presents Positive New Data at the 60th Annual American Society of Human Genetics (ASHG) for Patients with Type 1 Gaucher Disease]]> 04 Nov 2010 11:52:32 GMT <![CDATA[Directors/PDMR Shareholding]]> 02 Nov 2010 05:24:20 GMT <![CDATA[Total Voting Rights]]> 01 Nov 2010 01:36:40 GMT <![CDATA[Shire Receives INTUNIV™ Paragraph IV Notice Letter ]]> 01 Nov 2010 07:57:22 GMT <![CDATA[Continued excellent performance in Q3. Full year earnings expectations increased. New value in pipeline emerging]]> 29 Oct 2010 10:33:51 GMT <![CDATA[Shire Reports Positive Signal Finding Study of Investigative Use of Vyvanse® (lisdexamfetamine dimesylate) Capsules as Adjunctive Treatment in Major Depressive Disorder]]> 29 Oct 2010 10:25:05 GMT <![CDATA[Investigational Data Presented for INTUNIV™ (guanfacine) Extended-Release Tablets When Coadministered With Stimulants Showed ADHD Symptom Improvement in Overall, Morning and Evening Assessments]]> 28 Oct 2010 04:51:01 GMT <![CDATA[Shire Receives INTUNIV™ Paragraph IV Notice Letter]]> 26 Oct 2010 11:39:54 GMT <![CDATA[Third quarter 2010 results date notification - October 29, 2010]]> 18 Oct 2010 03:43:56 GMT <![CDATA[Shire Acquires 99.21% of the shares of Movetis N.V. and Announces Commencement of Squeeze-Out Tender Period]]> 13 Oct 2010 10:19:46 GMT <![CDATA[Shire Appoints Philip J. Vickers, PhD as Senior Vice President of Research & Development for Human Genetic Therapies Business]]> 11 Oct 2010 11:51:13 GMT <![CDATA[Total Voting Rights]]> 01 Oct 2010 03:59:10 GMT <![CDATA[Shire Announces Results of the Tender Offer for Movetis NV and Commencement of Squeeze-Out Tender Period]]> 30 Sep 2010 09:45:57 GMT <![CDATA[“Fact or Fiction: ADHD in America, a Capitol Hill Forum” ]]> 16 Sep 2010 11:42:10 GMT <![CDATA[Shire Update on ProAmatine® (midodrine HCl)]]> 13 Sep 2010 09:26:13 GMT <![CDATA[Shire Expands Pipeline to Treat Orphan Muscle Diseases through Collaboration with Acceleron Pharma]]> 09 Sep 2010 12:01:00 GMT <![CDATA[Shire Announces Commencement of Tender Offer to Acquire Movetis NV]]> 06 Sep 2010 06:15:02 GMT <![CDATA[Elections for Interim Dividend in Respect of the Six Months to June 30, 2010]]> 01 Sep 2010 03:35:37 GMT <![CDATA[Total Voting Rights]]> 01 Sep 2010 03:22:15 GMT <![CDATA[Shire Announces Support for Inflammatory Bowel Disease (IBD) Fellowships at Leading Medical Institutions Nationwide]]> 31 Aug 2010 03:49:07 GMT <![CDATA[Shire Announces European Approval of VPRIV® (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease]]> 26 Aug 2010 04:11:56 GMT <![CDATA[Notification of major interests in shares]]> 26 Aug 2010 03:29:32 GMT <![CDATA[Pentasa® - Shire Receives Ruling From FDA on Citizen’s Petition]]> 24 Aug 2010 04:40:00 GMT <![CDATA[Correction - Director/PDMR Shareholding]]> 20 Aug 2010 04:09:27 GMT <![CDATA[Statement re ProAmatine]]> 17 Aug 2010 07:00:20 GMT <![CDATA[Director/PDMR Shareholding]]> 17 Aug 2010 04:15:45 GMT <![CDATA[Half Yearly Report]]> 11 Aug 2010 11:41:35 GMT <![CDATA[Shire agrees to divest Daytrana® (methylphenidate transdermal system) CII to Noven Pharmaceuticals, Inc.; Shire’s 2010 earnings outlook unchanged]]> 10 Aug 2010 09:08:29 GMT <![CDATA[Director/PDMR Shareholding]]> 05 Aug 2010 04:42:58 GMT <![CDATA[Published Study Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Provided Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD]]> 05 Aug 2010 04:00:20 GMT <![CDATA[Study Published in the New England Journal of Medicine Demonstrates Efficacy and Favourable Safety Profile of Firazyr® (Icatibant) for the Treatment of Hereditary Angioedema (HAE) Attacks]]> 04 Aug 2010 04:35:28 GMT <![CDATA[Shire delivers excellent Q2 performance with total revenues up 35%. Full year earnings expectations raised.]]> 04 Aug 2010 11:49:10 GMT <![CDATA[Shire Proposes to Expand Specialist Gastrointestinal Portfolio]]> 03 Aug 2010 12:10:50 GMT <![CDATA[Shire Appoints Gráinne Higgins Global Vice President of Human Resources for Human Genetic Therapies Business ]]> 02 Aug 2010 05:56:46 GMT <![CDATA[Total Voting Rights]]> 02 Aug 2010 01:07:50 GMT <![CDATA[Nonsafety voluntary recall and withdrawal of a limited portion of Daytrana® (methylphenidate transdermal system) patches]]> 20 Jul 2010 07:01:41 GMT <![CDATA[Second quarter 2010 results date notification – August 4, 2010]]> 15 Jul 2010 11:23:54 GMT <![CDATA[Lialda® - Shire Files Suit against Cadila Healthcare Limited, doing business as Zydus Cadila and Zydus Pharmaceuticals (USA), Inc.]]> 08 Jul 2010 06:55:26 GMT <![CDATA[FDA Approves Daytrana® (methylphenidate transdermal system) CII for the Treatment of ADHD in Adolescents]]> 06 Jul 2010 02:19:08 GMT <![CDATA[Total Voting Rights]]> 01 Jul 2010 05:37:33 GMT <![CDATA[Data Presented at the European Working Group on Gaucher Disease Demonstrate Continuous Improvements in Bone Mineral Density for VPRIV® (velaglucerase alfa) through 69 months]]> 01 Jul 2010 02:17:13 GMT <![CDATA[Shire Purchases Strategic Site in Massachusetts]]> 30 Jun 2010 05:04:16 GMT <![CDATA[Shire named Company of the Year at Mediscience Awards]]> 28 Jun 2010 12:09:26 GMT <![CDATA[Shire Receives CHMP Positive Opinion for VPRIV™ (velaglucerase alfa) for the Treatment of Type 1 Gaucher Disease in the European Union]]> 25 Jun 2010 01:40:04 GMT <![CDATA[Director/PDMR Shareholding]]> 21 Jun 2010 03:53:34 GMT <![CDATA[Two New Board Directors Appointed]]> 17 Jun 2010 10:28:28 GMT <![CDATA[Shire Receives LIALDA® Paragraph IV Notice Letter from Zydus Pharmaceuticals]]> 28 May 2010 08:08:22 GMT <![CDATA[Study Evaluated Vyvanse® (lisdexamfetamine dimesylate) Capsules CII Efficacy and Safety in Adolescents with ADHD]]> 25 May 2010 06:29:02 GMT <![CDATA[Shire Receives 2010 Corporate Award from the National Organization for Rare Disorders (NORD) for the Development of VPRIV (velaglucerase alfa for injection) ]]> 19 May 2010 01:22:36 GMT <![CDATA[Total Voting Rights]]> 04 May 2010 05:05:52 GMT <![CDATA[FDA Approves Labeling Change for Vyvanse® (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD1]]> 1-4]]> 04 May 2010 05:03:24 GMT <![CDATA[Shire's replenished portfolio drives excellent quarterly performance]]> 29 Apr 2010 03:43:38 GMT <![CDATA[Results of the Annual General Meeting held on April 27, 2010]]> 27 Apr 2010 03:56:00 GMT <![CDATA[First quarter 2010 results date notification – April 29, 2010]]> 20 Apr 2010 10:11:12 GMT <![CDATA[Total Voting Rights]]> 01 Apr 2010 03:56:04 GMT <![CDATA[Director/PDMR Shareholding]]> 01 Apr 2010 03:33:25 GMT <![CDATA[Annual Information Update]]> 01 Apr 2010 03:26:34 GMT <![CDATA[Annual Report and Accounts]]> 25 Mar 2010 04:48:27 GMT <![CDATA[Shire Presents Positive Data for Patients with Type 1 Gaucher Disease Who Switched to VPRIVTM]]> 25 Mar 2010 10:36:54 GMT <![CDATA[Director/PDMR Shareholding]]> 18 Mar 2010 02:50:08 GMT <![CDATA[New Board Director Appointed]]> 15 Mar 2010 01:42:24 GMT <![CDATA[Director/PDMR Shareholding]]> 11 Mar 2010 02:56:55 GMT <![CDATA[Director/PDMR Shareholding]]> 09 Mar 2010 02:53:41 GMT <![CDATA[Director/PDMR Shareholding]]> 05 Mar 2010 04:10:58 GMT <![CDATA[District Court Upholds FDA’s Grant of 5-Year Market Exclusivity to VYVANSE®]]> 04 Mar 2010 06:02:20 GMT <![CDATA[Director/PDMR Shareholding]]> 03 Mar 2010 06:55:29 GMT <![CDATA[Director/PDMR Shareholding]]> 03 Mar 2010 04:14:36 GMT <![CDATA[Supplementary Reporting Announcement]]> 02 Mar 2010 03:13:11 GMT <![CDATA[Elections for Interim Dividend in Respect of the Six Months to December 31, 2009]]> 01 Mar 2010 03:52:05 GMT <![CDATA[Total Voting Rights]]> 01 Mar 2010 12:08:14 GMT <![CDATA[March is Kidney Health Month]]> 01 Mar 2010 10:59:46 GMT <![CDATA[Mars est le mois de la santé rénale]]> 01 Mar 2010 10:28:57 GMT <![CDATA[Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease]]> 26 Feb 2010 11:11:06 GMT <![CDATA[FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease]]> 26 Feb 2010 10:57:11 GMT <![CDATA[Shire Supports Rare Disease Day 2010 ]]> 26 Feb 2010 12:00:15 GMT <![CDATA[Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA)]]> 24 Feb 2010 11:14:01 GMT <![CDATA[Excellent results in a transformational year for Shire; core product sales up 25%]]> 19 Feb 2010 11:37:50 GMT <![CDATA[Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naïve Patients with Type 1 Gaucher Disease]]> 11 Feb 2010 11:46:51 GMT <![CDATA[Full Year 2009 results date notification – 19 February 2010]]> 04 Feb 2010 12:00:38 GMT <![CDATA[Shire to Present Important Study Findings for Gaucher Disease Treatment and GLD Development Program at the Lysosomal Disease Network (LDN) World Symposium]]> 03 Feb 2010 11:51:44 GMT <![CDATA[VYVANSE® — new ADHD treatment option — now available in Canada]]> 01 Feb 2010 12:09:12 GMT <![CDATA[Total Voting Rights]]> 01 Feb 2010 07:42:13 GMT <![CDATA[Notification of major interests in shares]]> 26 Jan 2010 06:26:05 GMT <![CDATA[Directorate Change]]> 18 Jan 2010 11:40:48 GMT <![CDATA[Total Voting Rights]]> 04 Jan 2010 02:47:31 GMT <![CDATA[Director/PDMR Shareholding]]> 29 Dec 2009 02:35:54 GMT <![CDATA[Dr Michael Rosenblatt to step down as non-executive director]]> 23 Dec 2009 04:39:14 GMT <![CDATA[Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA)]]> 22 Dec 2009 01:50:53 GMT <![CDATA[Shire Expands its Award-Winning ADHD Support Resource, ADHDSupport.com, by Launching an ADHD Twitter™ Page]]> 21 Dec 2009 02:19:15 GMT <![CDATA[Membership of Board Committees]]> 16 Dec 2009 07:13:47 GMT <![CDATA[Director/PDMR Shareholding]]> 16 Dec 2009 07:11:16 GMT <![CDATA[Director/PDMR Shareholding]]> 14 Dec 2009 07:08:16 GMT <![CDATA[Director/PDMR Shareholding]]> 11 Dec 2009 04:48:31 GMT <![CDATA[Notification of major interests in shares]]> 07 Dec 2009 01:09:04 GMT <![CDATA[Non-safety-related voluntary recall of a limited portion of Daytrana® (methylphenidate transdermal system) patches announced]]> 04 Dec 2009 09:27:00 GMT <![CDATA[Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic]]> 02 Dec 2009 12:50:15 GMT <![CDATA[Total Voting Rights]]> 01 Dec 2009 08:32:11 GMT <![CDATA[Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease]]> 24 Nov 2009 12:47:08 GMT <![CDATA[Block listing six monthly return]]> 23 Nov 2009 03:46:42 GMT <![CDATA[PDMR Shareholding ]]> 12 Nov 2009 03:03:16 GMT <![CDATA[Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking VYVANSE® (lisdexamfetamine dimesylate) Capsules CII]]> 12 Nov 2009 03:01:13 GMT <![CDATA[Shire Re-Launches FOCUS, an Online, Personalized Patient Support Program for Adults with ADHD Taking Vyvanse® (lisdexamfetamine dimesylate) Capsules CII]]> 11 Nov 2009 08:32:49 GMT <![CDATA[FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease]]> 04 Nov 2009 02:45:32 GMT <![CDATA[Directors/PDMR Shareholding]]> 03 Nov 2009 02:43:18 GMT <![CDATA[Total Voting Rights]]> 02 Nov 2009 02:40:30 GMT <![CDATA[New Shire Board member]]> 02 Nov 2009 02:37:46 GMT <![CDATA[Shire Reports Tolerability and Clinical Effects Results of DAYTRANA® (methylphenidate transdermal system) from Study in Adolescents with ADHD]]> 30 Oct 2009 02:33:19 GMT <![CDATA[Shire continues to deliver excellent growth from core products]]> 30 Oct 2009 02:18:34 GMT <![CDATA[Shire Secures European Wide Label Extension for FOSRENOL® in Chronic Kidney Disease]]> 28 Oct 2009 01:57:51 GMT <![CDATA[FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity]]> 26 Oct 2009 05:02:20 GMT <![CDATA[Third quarter 2009 results date notification – October 30, 2009]]> 22 Oct 2009 03:15:37 GMT <![CDATA[Shire Targets Fourth Quarter Filing of BLA for REPLAGAL® for Fabry Disease with U.S. FDA ]]> 21 Oct 2009 02:30:12 GMT <![CDATA[Shire voluntarily enables further access to HIV/AIDS medicines for Rwanda]]> 19 Oct 2009 01:37:50 GMT <![CDATA[Holding(s) in Company]]> 15 Oct 2009 02:28:53 GMT <![CDATA[Shire and Sandoz Settle All Pending Litigation Concerning ADDERALL XR®]]> 13 Oct 2009 02:25:30 GMT <![CDATA[Data from a head-to-head crossover study evaluating FOSRENOL® and sevelamer published today]]> 07 Oct 2009 02:23:59 GMT <![CDATA[Total Voting Rights]]> 01 Oct 2009 02:22:52 GMT <![CDATA[Director/PDMR Shareholding]]> 25 Sep 2009 02:20:51 GMT <![CDATA[Director/PDMR Shareholding]]> 22 Sep 2009 02:19:16 GMT <![CDATA[Director/PDMR Shareholding]]> 18 Sep 2009 02:17:47 GMT <![CDATA[Celebrity dancer, Karina Smirnoff, speaks out for the first time on how ADHD has impacted her life]]> 16 Sep 2009 01:55:48 GMT <![CDATA[Update on velaglucerase alfa]]> 08 Sep 2009 03:52:49 GMT <![CDATA[Director/PDMR Shareholding]]> 04 Sep 2009 01:53:16 GMT <![CDATA[Director/PDMR Shareholding]]> 03 Sep 2009 01:49:51 GMT <![CDATA[Total Voting Rights]]> 01 Sep 2009 04:14:13 GMT <![CDATA[Elections for interim dividend in respect of the six months to June 30, 2009]]> 01 Sep 2009 04:10:41 GMT <![CDATA[Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials]]> 01 Sep 2009 04:08:30 GMT <![CDATA[Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform]]> 24 Aug 2009 04:17:24 GMT <![CDATA[Half Yearly Report]]> 21 Aug 2009 04:20:28 GMT <![CDATA[Director/PDMR Shareholding]]> 19 Aug 2009 03:41:19 GMT <![CDATA[Shire Initiates Two Adult ADHD Outreach Programs]]> 17 Aug 2009 01:10:34 GMT <![CDATA[Membership of Board Committees]]> 07 Aug 2009 10:55:51 GMT <![CDATA[Q2 results - Core portfolio of products delivers 20% sales growth]]> 05 Aug 2009 01:59:15 GMT <![CDATA[Total Voting Rights]]> 03 Aug 2009 03:57:40 GMT <![CDATA[Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA]]> 03 Aug 2009 11:29:38 GMT <![CDATA[Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse® (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration ]]> 22 Jul 2009 10:14:05 GMT <![CDATA[Second quarter 2009 results date notification – August 5, 2009]]> 21 Jul 2009 03:43:51 GMT <![CDATA[Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease]]> 16 Jul 2009 03:41:49 GMT <![CDATA[Message from Sylvie Grégoire, President, Human Genetic Therapies regarding the MLD experimental drug]]> 16 Jul 2009 03:38:42 GMT <![CDATA[Dr Jeffrey Leiden appointed to Vertex Board.]]> 08 Jul 2009 03:37:18 GMT <![CDATA[Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease]]> 06 Jul 2009 03:33:17 GMT <![CDATA[Total Voting Rights]]> 01 Jul 2009 03:30:16 GMT <![CDATA[Study Showed VYVANSE® (lisdexamfetamine dimesylate) CII Provided Significant Efficacy at 14 Hours After Administration in Adults with ADHD in an Adult Simulated Workplace Environment]]> 01 Jul 2009 03:26:05 GMT <![CDATA[New Study in Women with Fabry Disease, Demonstrates Significant Benefits of Treatment with REPLAGAL® (agalsidase alfa) 0.2mg/kg on Kidney Function, Heart Function and Burden of Disease]]> 16 Jun 2009 03:22:16 GMT <![CDATA[Total Voting Rights]]> 01 Jun 2009 03:19:53 GMT <![CDATA[FDA Approves Labeling Change for VYVANSE® (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD]]> 01 Jun 2009 03:13:55 GMT <![CDATA[Block Listing Six Monthly Return]]> 26 May 2009 10:51:13 GMT <![CDATA[Director/PDMR Shareholding]]> 22 May 2009 10:25:24 GMT <![CDATA[New Study Evaluating the ADHD Medication VYVANSE® (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC® 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI)]]> 22 May 2009 10:23:43 GMT <![CDATA[Results from a European Caregiver Survey Highlight the Impact of Attention Deficit Hyperactivity Disorder (ADHD) on the Child and the Family ]]> 1...]]> 21 May 2009 10:22:09 GMT <![CDATA[Shire to Present New Scientific Data on its ADHD Treatments at a National Scientific Meeting of Psychiatrists on May 18]]> 15 May 2009 09:21:30 GMT <![CDATA[Director/PDMR Shareholding]]> 12 May 2009 02:40:14 GMT <![CDATA[Total Voting Rights]]> 01 May 2009 02:34:20 GMT <![CDATA[Shire begins the year with a strong performance]]> 30 Apr 2009 02:33:31 GMT <![CDATA[Results of the Annual General Meeting held on April 28, 2009]]> 28 Apr 2009 02:31:30 GMT <![CDATA[First quarter 2009 results date notification – April 30, 2009]]> 20 Apr 2009 08:49:20 GMT <![CDATA[Shire files lawsuit against Natco Pharma for infringement of FOSRENOL® (lanthanum carbonate) patents]]> 02 Apr 2009 08:46:29 GMT <![CDATA[Annual Information Update]]> 01 Apr 2009 08:45:18 GMT <![CDATA[Director/PDMR Shareholding]]> 01 Apr 2009 08:31:42 GMT <![CDATA[Notification of major interest in shares]]> 01 Apr 2009 08:28:57 GMT <![CDATA[Total Voting Rights]]> 01 Apr 2009 08:24:09 GMT <![CDATA[Shire and GlaxoSmithKline enter agreement to co-promote VYVANSE® (lisdexamfetamine dimesylate) CII for the treatment of adults with ADHD]]> 31 Mar 2009 02:46:25 GMT <![CDATA[Publication of Shire plc's Annual Report 2008]]> 25 Mar 2009 02:45:27 GMT <![CDATA[Saving a playground, lifting a neighborhood]]> 21 Mar 2009 02:42:00 GMT <![CDATA[Shire files lawsuit against Mylan for infringement of FOSRENOL® (lanthanum carbonate) patent]]> 20 Mar 2009 02:37:09 GMT <![CDATA[Non-safety-related voluntary market withdrawal of a limited portion of DAYTRANA® (methylphenidate transdermal system) patches announced ]]> 20 Mar 2009 02:33:00 GMT <![CDATA[Holding(s) in Company ]]> 19 Mar 2009 02:32:26 GMT <![CDATA[Shire files lawsuit against Barr Laboratories for infringement of FOSRENOL® (lanthanum carbonate) patents]]> 16 Mar 2009 02:29:08 GMT <![CDATA[Shire withdraws European Application for DAYTRANA™ (methylphenidate transdermal system) ]]> 16 Mar 2009 10:08:09 GMT <![CDATA[World Kidney Day press release]]> 12 Mar 2009 10:04:45 GMT <![CDATA[Holding(s) in Company ]]> 12 Mar 2009 10:04:05 GMT <![CDATA[Holding(s) in Company]]> 09 Mar 2009 10:03:29 GMT <![CDATA[Holding(s) in Company]]> 05 Mar 2009 10:02:53 GMT <![CDATA[Elections for interim dividend in respect of the six months to December 31, 2008]]> 02 Mar 2009 09:47:39 GMT <![CDATA[Total Voting Rights]]> 02 Mar 2009 09:39:21 GMT <![CDATA[Shire HGT Announces Support for Rare Disease Day]]> 26 Feb 2009 09:36:44 GMT <![CDATA[Director/PDMR Shareholding]]> 23 Feb 2009 09:33:12 GMT <![CDATA[Director/PDMR Shareholding]]> 23 Feb 2009 09:19:50 GMT <![CDATA[Shire to enter European ADHD market with the acquisition of EQUASYM® IR and XL]]> 20 Feb 2009 09:15:32 GMT <![CDATA[Shire Announces Opening of Office in Japan]]> 20 Feb 2009 09:12:27 GMT <![CDATA[Shire delivers excellent growth for the year, with the new product portfolio achieving sales of $1 billion]]> 19 Feb 2009 09:07:28 GMT <![CDATA[Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan]]> 09 Feb 2009 09:06:10 GMT <![CDATA[Full Year 2008 results date notification – 19 February 2009]]> 09 Feb 2009 08:58:10 GMT <![CDATA[Change to Director's details]]> 05 Feb 2009 08:56:00 GMT <![CDATA[Total Voting Rights]]> 02 Feb 2009 08:54:31 GMT <![CDATA[Total Voting Rights]]> 05 Jan 2009 08:51:33 GMT <![CDATA[Director/PDMR Shareholding]]> 17 Dec 2008 03:56:10 GMT <![CDATA[Total Voting Rights]]> 01 Dec 2008 10:32:54 GMT <![CDATA[Block Listing Six Monthly Return]]> 25 Nov 2008 10:32:07 GMT <![CDATA[Director/PDMR Shareholding]]> 25 Nov 2008 10:31:25 GMT <![CDATA[Investor seminar ]]> 18 Nov 2008 03:46:57 GMT <![CDATA[Confirmation of HGT business day - 18th November 2008]]> 12 Nov 2008 03:49:32 GMT <![CDATA[Director/PDMR Shareholding]]> 07 Nov 2008 03:51:03 GMT <![CDATA[Shire successfully settles former TKT shareholder appraisal rights litigation]]> 05 Nov 2008 10:30:25 GMT <![CDATA[Directors/PDMR Shareholding]]> 04 Nov 2008 10:27:03 GMT <![CDATA[Total Voting Rights]]> 03 Nov 2008 10:26:23 GMT <![CDATA[Shire’s new product portfolio delivers strong quarterly performance]]> 29 Oct 2008 10:25:39 GMT <![CDATA[Third quarter 2008 results date notification – 29 October 2008]]> 15 Oct 2008 10:22:55 GMT <![CDATA[CHANGE OF NAME TO SHIRE PLC]]> 01 Oct 2008 10:22:16 GMT <![CDATA[Total Voting Rights]]> 01 Oct 2008 10:21:32 GMT <![CDATA[Correction - Results of the Annual General Meeting held on September 24, 2008]]> 25 Sep 2008 10:20:02 GMT <![CDATA[Results of the Annual General Meeting held on September 24, 2008]]> 24 Sep 2008 10:19:17 GMT <![CDATA[Director/PDMR Shareholding]]> 23 Sep 2008 10:18:23 GMT <![CDATA[Notification of Acquisition of American Depository Shares by Persons Discharging Managerial Responsibilities]]> 12 Sep 2008 10:14:51 GMT <![CDATA[Notification of major interests in shares]]> 08 Sep 2008 10:14:07 GMT <![CDATA[Total Voting Rights]]> 01 Sep 2008 03:07:26 GMT <![CDATA[Elections for interim dividend in respect of the half year for the six months ended June, 30 2008]]> 01 Sep 2008 03:06:41 GMT <![CDATA[Notification of Acquisition of American Depository Shares by Persons Discharging Managerial Responsibilities]]> 01 Sep 2008 10:20:49 GMT <![CDATA[Notice of the 2008 Annual General Meeting and Proxy Card]]> 22 Aug 2008 03:05:55 GMT <![CDATA[SHIRE ANNOUNCES HOLDING OF 81% IN JERINI AG AND PUBLICATION OF OFFER DOCUMENT]]> 13 Aug 2008 03:05:07 GMT <![CDATA[Half Yearly Report ]]> 07 Aug 2008 10:09:39 GMT <![CDATA[Notification of Acquisition of Shares by Director/Person Discharging Managerial Responsibilities]]> 06 Aug 2008 02:54:19 GMT <![CDATA[Director/PDMR Shareholding]]> 06 Aug 2008 02:53:31 GMT <![CDATA[Notification of Acquisition of American Depository Shares by a Director/Person Discharging Managerial Responsibilities]]> 04 Aug 2008 02:52:50 GMT <![CDATA[Director/PDMR Shareholding]]> 04 Aug 2008 02:50:45 GMT <![CDATA[Notification of Acquisition of American Depository Shares by a Director/Person Discharging Managerial Responsibilities]]> 04 Aug 2008 02:49:43 GMT <![CDATA[CNBC interview with Angus Russell following Shire's Q2 results 2008]]> 01 Aug 2008 02:48:14 GMT <![CDATA[Shire delivers strong quarter: driven by $243m of new product sales (+164% YOY growth). Revenue guidance upgraded.]]> 31 Jul 2008 02:47:30 GMT <![CDATA[Tatjana May appointed Chair of Shire’s Corporate Responsibility Committee]]> 30 Jul 2008 02:45:49 GMT <![CDATA[Shire Appoints Dr. Jeffrey Jonas Senior Vice President, R&D, Specialty Pharmaceuticals]]> 23 Jul 2008 02:44:26 GMT <![CDATA[Robin Buchanan to step down as non-executive director on completion of term of office]]> 21 Jul 2008 02:33:08 GMT <![CDATA[Jerini Receives European Commission Approval for FIRAZYR® (Icatibant) in the Treatment of HAE]]> 15 Jul 2008 02:32:27 GMT <![CDATA[Second quarter 2008 results date notification - 31 July 2008]]> 04 Jul 2008 02:31:36 GMT <![CDATA[Shire erweitert HGT-Portfolio mit neuem Orphan-Arznei-mittel – Einführung in der EU steht unmittelbar bevor]]> 03 Jul 2008 02:30:18 GMT <![CDATA[Shire to add new orphan drug to its HGT portfolio – EU launch imminent]]> 03 Jul 2008 02:28:48 GMT <![CDATA[Director/PDMR Shareholding]]> 19 Jun 2008 02:27:01 GMT <![CDATA[Notification of Acquisition of American Depository Shares by Person Discharging Managerial Responsibilities]]> 16 Jun 2008 02:26:02 GMT <![CDATA[Graham Hetherington appointed Chief Financial Officer and Board Director at Shire]]> 10 Jun 2008 02:24:05 GMT <![CDATA[Shire Announces Approval of ELAPRASE® (idursulfase) in Brazil ]]> 27 May 2008 02:21:46 GMT <![CDATA[Application for Listing of Shire Limited Ordinary Shares]]> 23 May 2008 02:20:26 GMT <![CDATA[Court Approves Scheme of Arrangement]]> 22 May 2008 02:19:29 GMT <![CDATA[Annual Information Update]]> 20 May 2008 02:06:58 GMT <![CDATA[Results of Court Meeting and Extraordinary General Meeting - Shareholders Approve Scheme of Arrangement and New Share Plans]]> 09 May 2008 02:04:50 GMT <![CDATA[Shire opens new office in Norway]]> 09 May 2008 01:58:23 GMT <![CDATA[Shire welcomes the Court of Appeal's decision that NICE review of Alzheimer's drugs was procedurally unfair]]> 01 May 2008 01:56:55 GMT <![CDATA[Publication of Supplementary Prospectus]]> 28 Apr 2008 01:51:18 GMT <![CDATA[Following a good start to the year Shire reaffirms full year 2008 financial guidance]]> 25 Apr 2008 01:44:49 GMT <![CDATA[Dr Michael Rosenblatt appointed Non-Executive Director at Shire]]> 24 Apr 2008 01:43:53 GMT <![CDATA[Shire enhances its orphan drug pipeline with the acquisition of a new clinical candidate for Metachromatic Leukodystrophy]]> 24 Apr 2008 01:43:06 GMT <![CDATA[FDA Approves VYVANSE (TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults]]> 23 Apr 2008 01:41:33 GMT <![CDATA[New Shire Holding Company Proposal]]> 16 Apr 2008 01:40:07 GMT <![CDATA[First Quarter 2008 Results Date Notification]]> 16 Apr 2008 01:35:28 GMT <![CDATA[SHIRE TO INTRODUCE A NEW UK LISTED HOLDING COMPANY]]> 15 Apr 2008 01:34:41 GMT <![CDATA[Annual Report and Accounts for the year ended December 31, 2007]]> 04 Apr 2008 01:33:54 GMT <![CDATA[Movement of shares out of the Employee Benefit Trust ]]> 02 Apr 2008 01:33:03 GMT <![CDATA[Director/PDMR Shareholding]]> 31 Mar 2008 01:32:20 GMT <![CDATA[IFRS results for the year ending December 31, 2007 ]]> 25 Mar 2008 01:05:09 GMT <![CDATA[RENOVO ANNNOUNCES JUVISTA® PHASE 2 TRIAL RESULTS IN SCAR REVISION AND BREAST AUGMENTATION SURGERY ]]> 03 Mar 2008 01:04:13 GMT <![CDATA[Renovo announces results of latest Phase 2 studies of JUVISTA(R) (human recombinant TGF Beta 3)]]> 03 Mar 2008 01:01:14 GMT <![CDATA[Growing Support for World Kidney Day]]> 27 Feb 2008 01:00:09 GMT <![CDATA[Notification of Acquisition of American Depository Shares by Persons Discharging Managerial Responsibilities]]> 26 Feb 2008 12:59:21 GMT <![CDATA[Director/PDMR Shareholding ]]> 25 Feb 2008 12:58:41 GMT <![CDATA[CNBC interview with Matthew Emmens, CEO, following Shire’s full year 2007 results (video)]]> 21 Feb 2008 12:57:19 GMT <![CDATA[Q4, YEAR 2007 RESULTS]]> 21 Feb 2008 12:56:28 GMT <![CDATA[Correction]]> 20 Feb 2008 12:55:49 GMT <![CDATA[Healthcare Businesswomen’s Association Announces 2008 Woman of the Year, Charlotte Sibley, Senior Vice President, Leadership Development, Shire Pharmaceuticals]]> 19 Feb 2008 12:54:45 GMT <![CDATA[Shire HGT Announces Commitment to Continue Expansion in Massachusetts ]]> 14 Feb 2008 12:54:04 GMT <![CDATA[Shire’s ELAPRASE® (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome]]> 13 Feb 2008 12:53:27 GMT <![CDATA[Full Year 2007 results date notification – 21 February 2008]]> 12 Feb 2008 12:52:08 GMT <![CDATA[Shire Completes Fosrenol® Roll-Out in Major European Markets With Launch in Spain]]> 17 Jan 2008 12:51:23 GMT <![CDATA[Shire expands its gastrointestinal portfolio through in-licensing Celiac disease Phase 2 product from Alba Therapeutics Corporation]]> 14 Dec 2007 12:50:34 GMT <![CDATA[Board Changes]]> 13 Dec 2007 12:49:53 GMT <![CDATA[Permission granted to challenge the High Court ruling to restrict Alzheimers’ drugs access on the NHS]]> 06 Dec 2007 12:48:16 GMT <![CDATA[Shire Pharmaceuticals donates over 400 laptops ]]> 27 Nov 2007 12:47:29 GMT <![CDATA[Shire Human Genetic Therapies Appoints Dr. Whaijen Soo to Manage the R&D of its Expanding Treatment Portfolio]]> 20 Nov 2007 12:45:09 GMT <![CDATA[Shire pleased with Vyvanse growth - Reuters Health Summit (video)]]> 13 Nov 2007 12:44:09 GMT <![CDATA[Shire expands its Human Genetic Therapies pipeline through in-licensing agreement with Amicus Therapeutics]]> 08 Nov 2007 12:43:21 GMT <![CDATA[New non-clinical data links DYNEPO® (epoetin delta) to Reduced Angiogenic Potential ]]> 05 Nov 2007 12:42:26 GMT <![CDATA[Further upgrade to 2007 financial guidance based on strong revenue growth; VYVANSE™ demand on track]]> 01 Nov 2007 12:41:26 GMT <![CDATA[David Mott appointed Non Executive Director at Shire]]> 31 Oct 2007 12:18:34 GMT <![CDATA[Shire launches clinical study results website]]> 25 Oct 2007 12:14:20 GMT <![CDATA[Third quarter 2007 results date notification]]> 17 Oct 2007 12:10:43 GMT <![CDATA[Reinforcing strategic focus on growth-driving global products]]> 08 Oct 2007 12:07:01 GMT <![CDATA[Shire’s ELAPRASE® (idursulfase) Approved in Japan For the Treatment of Hunter Syndrome]]> 04 Oct 2007 12:05:12 GMT <![CDATA[Shire to support appeal against outcome of Judicial Review of NICE guidance which denies newly diagnosed patients with mild Alzheimer's disease access to drugs on the NHS]]> 01 Oct 2007 11:27:42 GMT <![CDATA[Families Invited to Celebrate "Shire Day" at Boston Children’s Museum]]> 28 Sep 2007 11:25:40 GMT <![CDATA[Shire launches Clinical Study Results Database]]> 28 Sep 2007 11:24:31 GMT <![CDATA[Shire Appoints Sylvie Gregoire President of Human Genetic Therapies Business]]> 24 Sep 2007 11:23:45 GMT <![CDATA[IFRS Information – First half of 2007]]> 13 Sep 2007 11:22:58 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Director/PDMR.]]> 12 Sep 2007 11:20:53 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a PDMR.]]> 12 Sep 2007 11:19:59 GMT <![CDATA[Statistically significant efficacy of Juvista® demonstrated in phase 2 trial using drug substance manufactured by Lonza Biologics]]> 12 Sep 2007 11:18:49 GMT <![CDATA[Revised NICE Guidance on Alzheimer's disease (AD) confirms reliance on the MMSE1 for majority of patients and continued exclusion from NHS treatment for those with mild AD]]> 1 for majority of patients and continued exclusion from NHS treatment for those with mild AD]]> 07 Sep 2007 11:17:48 GMT <![CDATA[New partnership promises bright future for organic chemistry in the UK]]> 05 Sep 2007 11:16:08 GMT <![CDATA[Shire voluntarily withdraws a limited portion of DAYTRANA™ (methylphenidate transdermal system) patches]]> 04 Sep 2007 11:15:18 GMT <![CDATA[Shire supports Canada's Access to Medicines Regime]]> 15 Aug 2007 11:14:39 GMT <![CDATA[Expiry of Hart-Scott-Rodino waiting period for JUVISTA® (human TGFβ3)]]> 15 Aug 2007 11:13:54 GMT <![CDATA[Majority of patients with mild Alzheimer’s disease will remain excluded from NHS treatment despite revisions to NICE Guidance]]> 10 Aug 2007 11:13:16 GMT <![CDATA[Uncertainty remains for newly diagnosed patients with mild Alzheimer’s disease and their families as the Judicial Review judgement is revealed]]> 10 Aug 2007 11:12:29 GMT <![CDATA[Total Voting Rights]]> 02 Aug 2007 11:11:56 GMT <![CDATA[CNBC interview with Matthew Emmens, CEO, following Shire’s Q2 results (video)]]> 31 Jul 2007 11:10:50 GMT <![CDATA[Application for Share Listing]]> 27 Jul 2007 11:09:24 GMT <![CDATA[2007 guidance upgraded as revenue growth accelerates]]> 26 Jul 2007 11:08:30 GMT <![CDATA[Shire Board Changes]]> 25 Jul 2007 11:07:45 GMT <![CDATA[Second quarter 2007 results – Timing of investor / analyst meeting changed to 14:30 BST / 9:30 EDT]]> 19 Jul 2007 11:06:53 GMT <![CDATA[Second quarter 2007 results date notification - 26 July 2007]]> 18 Jul 2007 11:06:05 GMT <![CDATA[Total Voting Rights]]> 02 Jul 2007 11:05:20 GMT <![CDATA[Shire Announces Filing of VYVANSE™ (lisdexamfetamine dimesylate) for the Treatment of ADHD in Adults ]]> 29 Jun 2007 11:04:31 GMT <![CDATA[Shire Demonstrates Commitment To Improving Patient Adherence In End Stage Renal Disease As New Phosphate-Binder FOSRENOL® Launches In Europe]]> 25 Jun 2007 11:03:45 GMT <![CDATA[Notification of major interests in shares]]> 25 Jun 2007 11:02:47 GMT <![CDATA[Shire Receives Approvable Letter from FDA for INTUNIV™ (guanfacine) Extended Release, a Nonstimulant for the Treatment of ADHD]]> 21 Jun 2007 11:01:44 GMT <![CDATA[Shire in-licenses JUVISTA® (human TGFβ3) from Renovo]]> 20 Jun 2007 11:00:40 GMT <![CDATA[Notification of major interests in shares]]> 20 Jun 2007 10:59:45 GMT <![CDATA[Results of the Annual General Meeting]]> 20 Jun 2007 10:58:58 GMT <![CDATA[Annual Information Update]]> 20 Jun 2007 10:58:11 GMT <![CDATA[Goldman Sachs Group and its holdings in Shire]]> 19 Jun 2007 10:57:23 GMT <![CDATA[Total Voting Rights]]> 01 Jun 2007 10:56:40 GMT <![CDATA[Block Listing Six Monthly Return]]> 29 May 2007 10:54:46 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities]]> 22 May 2007 10:53:39 GMT <![CDATA[FDA Issues Approvable Letter for SPD465 (Triple-Bead Mixed Amphetamine Salts) for the Treatment of ADHD in Adults]]> 19 May 2007 10:51:45 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities]]> 18 May 2007 10:50:58 GMT <![CDATA[Shire to Present New Scientific Data on ADHD Treatment Portfolio at APA Annual Meeting]]> 14 May 2007 10:49:52 GMT <![CDATA[Shire welcomes early date for Judicial Review of NICE decision on Alzheimer’s treatments]]> 11 May 2007 10:49:01 GMT <![CDATA[Retirement of Non-Executive Director and notification of the Exercise of an Option and Sale of Shares]]> 11 May 2007 10:48:26 GMT <![CDATA[Shire plc announces the Exercise of Over-Allotment Option in relation to Convertible Bond Offering outside the United States and to non-US persons only]]> 08 May 2007 10:47:08 GMT <![CDATA[VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD]]> 03 May 2007 10:46:02 GMT <![CDATA[VYVANSE™ (lisdexamfetamine dimesylate) Receives Final DEA Schedule Classification, Clearing Way for Launch of First Prodrug Stimulant for Treatment of ADHD]]> 03 May 2007 10:46:02 GMT <![CDATA[Shire announces the Pricing of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only]]> 02 May 2007 10:45:02 GMT <![CDATA[Shire announces refinancing of bank facilities connected with the recent acquisition of New River through the launch of US$1,000 million Convertible Bonds due 2014 to be offered outside the United States and to non-US persons only]]> 02 May 2007 10:44:15 GMT <![CDATA[Total Voting Rights]]> 01 May 2007 10:43:22 GMT <![CDATA[First quarter results - strong start to the year with upgraded guidance now including New River]]> 25 Apr 2007 10:42:19 GMT <![CDATA[Shire Completes Acquisition of New River]]> 20 Apr 2007 10:41:36 GMT <![CDATA[Shire Successfully Completes Tender Offer for New River Shares]]> 18 Apr 2007 10:40:05 GMT <![CDATA[FIRST QUARTER 2007 RESULTS DATE NOTIFICATION]]> 17 Apr 2007 10:39:22 GMT <![CDATA[Results of Extraordinary General Meeting held on 16 April 2007]]> 16 Apr 2007 10:38:31 GMT <![CDATA[Notification of major interests in shares]]> 16 Apr 2007 10:37:02 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust ]]> 10 Apr 2007 10:35:44 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 05 Apr 2007 10:34:57 GMT <![CDATA[Movement of shares out of the Employee Benefit Trust]]> 05 Apr 2007 10:34:13 GMT <![CDATA[Shire Executive Annual Incentive Plan]]> 04 Apr 2007 10:33:32 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 04 Apr 2007 10:32:38 GMT <![CDATA[Movement of shares out of the Employee Benefit Trust]]> 04 Apr 2007 10:31:46 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 03 Apr 2007 10:31:02 GMT <![CDATA[Application for share listing]]> 03 Apr 2007 10:30:17 GMT <![CDATA[Shire Executive Annual Incentive Plan]]> 02 Apr 2007 10:29:30 GMT <![CDATA[Total Voting Rights]]> 02 Apr 2007 10:26:10 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Non-Executive Director]]> 02 Apr 2007 10:25:06 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust ]]> 02 Apr 2007 10:23:59 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 29 Mar 2007 10:23:08 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 28 Mar 2007 10:22:32 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities]]> 28 Mar 2007 10:21:45 GMT <![CDATA[Judicial Review of NICE decision ]]> 27 Mar 2007 10:21:04 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 27 Mar 2007 10:20:16 GMT <![CDATA[Notice of EGM ]]> 26 Mar 2007 10:19:39 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 26 Mar 2007 10:14:46 GMT <![CDATA[IFRS results for the year ending December 31, 2006]]> 23 Mar 2007 10:13:44 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Person Discharging Managerial Responsibilities]]> 23 Mar 2007 10:12:56 GMT <![CDATA[Holding(s) in Company]]> 22 Mar 2007 10:12:09 GMT <![CDATA[Holding(s) in Company]]> 22 Mar 2007 10:11:24 GMT <![CDATA[Notification of the Exercise of an Option and Sale of Shares by a Director]]> 22 Mar 2007 10:10:42 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 22 Mar 2007 10:09:58 GMT <![CDATA[ADDERALL XR® - Shire Files Suit against Colony Pharmaceuticals, Inc., Actavis, Inc. and Actavis Group hf]]> 21 Mar 2007 10:08:49 GMT <![CDATA[Shire begins external search for President of successful Human Genetic Therapies business, on retirement of David Pendergast at the end of 2007]]> 20 Mar 2007 10:07:35 GMT <![CDATA[Shire Announces Expiration of Hart-Scott-Rodino Waiting Period]]> 19 Mar 2007 10:06:29 GMT <![CDATA[Correction to Purchase of Shares by Employee Benefit Trust]]> 19 Mar 2007 10:05:15 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 16 Mar 2007 05:23:09 GMT <![CDATA[New Human Cell-Produced Treatment for Anaemia Associated with Chronic Kidney Disease Now Available, Shire’s launch of DYNEPO® (epoetin delta) begins across Europe]]> 15 Mar 2007 05:21:03 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 15 Mar 2007 05:18:29 GMT <![CDATA[Purchase of shares by employee benefit trust]]> 14 Mar 2007 05:17:39 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 13 Mar 2007 05:16:34 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 12 Mar 2007 05:15:40 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 09 Mar 2007 05:14:49 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 08 Mar 2007 05:13:51 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 06 Mar 2007 05:12:46 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 06 Mar 2007 05:10:54 GMT <![CDATA[UK launch expands global reach of FOSRENOL®]]> 05 Mar 2007 05:09:18 GMT <![CDATA[Holding(s) in Company]]> 02 Mar 2007 05:07:55 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 02 Mar 2007 05:06:44 GMT <![CDATA[Purchase of Shares by Employee Benefit Trust]]> 02 Mar 2007 05:04:53 GMT <![CDATA[Director/PDMR Shareholding ]]> 28 Feb 2007 05:03:58 GMT <![CDATA[Holding(s) in Company]]> 28 Feb 2007 05:02:39 GMT <![CDATA[Holding(s) in Company]]> 28 Feb 2007 05:01:49 GMT <![CDATA[Holding(s) in Company]]> 28 Feb 2007 05:00:41 GMT <![CDATA[Holding(s) in Company]]> 28 Feb 2007 04:59:42 GMT <![CDATA[Holding(s) in Company]]> 28 Feb 2007 04:58:35 GMT <![CDATA[Movement of shares out of the Employee Benefit Trust]]> 27 Feb 2007 04:57:43 GMT <![CDATA[FDA Approval of VYVANSE™ as a Novel Treatment for ADHD ]]> 23 Feb 2007 04:56:43 GMT <![CDATA[Director/PDMR Shareholding]]> 23 Feb 2007 04:55:19 GMT <![CDATA[Employee Benefit Trust announcement]]> 23 Feb 2007 04:54:11 GMT <![CDATA[FOSRENOL® launches in United Kingdom today]]> 22 Feb 2007 04:52:24 GMT <![CDATA[Director/PDMR Shareholding]]> 22 Feb 2007 04:51:35 GMT <![CDATA[Shire agrees to acquire new river to gain full control of Vyvanseâ¢, its future flagship product for ADHD]]> 20 Feb 2007 04:50:17 GMT <![CDATA[Shire announces $800 million equity financing in connection with Acquisition Of New River]]> 20 Feb 2007 04:40:20 GMT <![CDATA[Result of equity placing]]> 20 Feb 2007 10:02:57 GMT <![CDATA[Results for the twelve months to December 31, 2006 - On time execution of operating plan delivers strong 2006 performance]]> 20 Feb 2007 10:01:42 GMT <![CDATA[Total Voting Rights]]> 15 Feb 2007 09:59:55 GMT <![CDATA[Full Year 2006 Results Date Notification - 23 February 2007]]> 14 Feb 2007 09:58:54 GMT <![CDATA[Movement of shares out of the Employee Benefit Trust]]> 12 Feb 2007 09:57:54 GMT <![CDATA[Goldman Sachs Group and its holdings in Shire]]> 25 Jan 2007 09:46:54 GMT <![CDATA[Shire licenses the North American rights for SPD754]]> 23 Jan 2007 09:44:05 GMT <![CDATA[Total Voting Rights]]> 18 Jan 2007 09:43:08 GMT <![CDATA[Goldman Sachs Group and its holdings in Shire]]> 12 Jan 2007 09:39:46 GMT <![CDATA[ELAPRASE® for the treatment of Hunter syndrome approved by the European Commission]]> 11 Jan 2007 09:34:04 GMT